ArticleFrontiers in veterinary science2022
Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs.
Article in Frontiers in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Bioactive Compounds and In Vitro Antibacterial Activity of Hemp Leaves and Inflorescences as Potential Functional Feed Ingredients for Canine Nutrition.Animals : an open access journal from MDPI · 2026Article
- Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.Frontiers in veterinary science · 2026Article
- Differences in Plasma Exposure of Cannabidiol and Cannabidiolic Acid Following Oral Administration to Horses.Journal of veterinary pharmacology and therapeutics · 2026Article
- An Exploratory Study of Cannabidiol as an Adjunctive Treatment for Refractory Epilepsy in Dogs.Animals : an open access journal from MDPI · 2025Article
- Extended Analysis of Status Epilepticus and Cluster Seizures in Dogs in the Context of Overall Epilepsy Incidence: 254 Cases.Animals : an open access journal from MDPI · 2025Article
- The Potential of Cannabidiol for Treating Canine Atopic Dermatitis.Veterinary sciences · 2025Review
- CBD for pets: navigating quality assurance, safety standards, and marketing strategies.Journal of cannabis research · 2025Review
- Cumulative Effects of Cannabis Oils on Body Temperature, Electrocardiography, Heart Rate Variability, Blood Pressure, and Respiratory Function in Telemetered Dogs.International journal of veterinary science and medicine · 2025Article
- Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs.Animals : an open access journal from MDPI · 2024Article
- Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review.Veterinary research communications · 2024Review
- Review
- Tolerability of 2 and 4 mg/kg Dosing Every 12 Hour of a Cannabidiol- and Cannabidiolic Acid-Rich Hemp Extract on Mixed-Breed Dogs Utilized for Teaching in a Closed Colony.Animals : an open access journal from MDPI · 2024Article
- Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog.Frontiers in veterinary science · 2024Article
- Efficacy and tolerability of full spectrum hemp oil in dogs living with pain in common household settings.Frontiers in veterinary science · 2024Article
- Safety study of cannabidiol products in healthy dogs.Frontiers in veterinary science · 2024Article
- Danish dog owners' use and the perceived effect of unlicensed cannabis products in dogs.PloS one · 2024Article
- Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge.Frontiers in veterinary science · 2023Review
- Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.International journal of molecular sciences · 2022Review
- Safety, Efficacy and Doxorubicin Pharmacokinetics During Cannabidiol/Cannabidiolic Acid Rich Hemp Oil Use in Dogs With Lymphoma Undergoing CHOP Chemotherapy.Journal of veterinary internal medicineArticle
- The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of cannabidiol (CBD) in childhood refractory seizures has become a common therapeutic approach for specific seizure disorders in human medicine. Similarly, there is an interest in using CBD, cannabidiolic acid (CBDA) or cannabinoid-rich hemp products in the treatment of idiopathic epilepsy in dogs. We aimed to examine a small cohort in a pilot investigation using a CBD and CBDA-rich hemp product for the treatment of refractory epileptic seizures in dogs. Fourteen dogs were examined in a 24-week randomized cross-over study being provided placebo or CBD/CBDA-rich hemp extract treatment at 2 mg/kg orally every 12 h for each 12-week arm of the study. Serum chemistry, complete blood counts, serum anti-seizure medication (ASM) concentrations and epileptic seizure frequency were followed over both arms of the cross-over trial. Results demonstrated that besides a mild increase in alkaline phosphatase, there were no alterations observed on routine bloodwork at 2, 6, and 12 weeks during either arm of the study. Epileptic seizure frequency decreased across the population from a mean of 8.0 ± 4.8 during placebo treatment to 5.0 ± 3.6 with CBD/CBDA-rich hemp extract (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.